State Street’s Rein Therapeutics RNTX Stock Holding History

State Street’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$395K	Buy	379,604 +303,700	+400%	+$367K	﹤0.01%	3650
2026 Q1	$98.7K	Hold	75,904	–	–	﹤0.01%	4029
2025 Q4	$88K	Buy	75,904 +59,900	+374%	+$82.5K	﹤0.01%	4065
2025 Q3	$18.3K	Hold	16,004	–	–	﹤0.01%	4254
2025 Q2	$22.4K	Hold	16,004	–	–	﹤0.01%	4190
2025 Q1	$28.3K	Hold	16,004	–	–	﹤0.01%	4166
2024 Q4	$36.8K	Buy	16,004 +5,600	+54%	+$17K	﹤0.01%	4155
2024 Q3	$36.8K	Hold	10,404	–	–	﹤0.01%	4144
2024 Q2	$28.8K	Buy	+10,404	New	+$42.8K	﹤0.01%	4235
2022 Q4	–	Sell	-5,104	Closed	-$21K	–	4904
2022 Q3	$21K	Hold	5,104	–	–	﹤0.01%	4827
2022 Q2	$27K	Buy	5,104 +1,544	+43%	+$14.2K	﹤0.01%	4835
2022 Q1	$36K	Hold	3,560	–	–	﹤0.01%	4845
2021 Q4	$40K	Hold	3,560	–	–	﹤0.01%	4732
2021 Q3	$73K	Hold	3,560	–	–	﹤0.01%	4606
2021 Q2	$89K	Buy	+3,560	New	+$88.8K	﹤0.01%	4384
2018 Q2	–	Sell	-1,893	Closed	-$309K	–	3807
2018 Q1	$309K	Buy	1,893 +270	+17%	+$48.1K	﹤0.01%	3499
2017 Q4	$342K	Buy	1,623 +764	+89%	+$183K	﹤0.01%	3504
2017 Q3	$229K	Buy	+859	New	+$215K	﹤0.01%	3586

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

State Street's RNTX Position: Q2 2026 in Review

State Street increased its Rein Therapeutics (RNTX) stake by 400% in Q2 2026, buying an estimated $367K and bringing the position to 379,604 shares worth $395K. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

State Street first reported a position in RNTX in Q3 2017 and has held it in 18 quarters since. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

State Street held 379,604 shares of Rein Therapeutics worth $395K as of Q2 2026.
State Street bought 303,700 Rein Therapeutics shares in Q2 2026, an estimated $367K.
Rein Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3650 holding.
State Street first reported a position in Rein Therapeutics in Q3 2017 and has held it in 18 quarters since.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.